

These documents have been translated from Japanese originals for reference purposes only. In the event of any discrepancy between these translated documents and the Japanese originals, the originals shall prevail.

September 29, 2025

NIHON KOHDEN CORPORATION (6849)

Stock Exchange Listing: Prime Market, Tokyo Stock Exchange
Head Office: Tokyo
Representative: Hirokazu Ogino, Representative Director, President and Chief Executive Officer
Contact: Fumio Izumida, Operating Officer, General Manager of Corporate Strategy Division
Phone: +81 / 3-5996-8003

Notice regarding Discontinuation of Providing Abbott Products in Japan

Nihon Kohden announces that it resolved at a meeting of the Board of Directors held today to terminate the distribution partnership agreement (“Agreement”) with Abbott Medical Japan LLC (“AMJ”) on the expiration date of December 31, 2026, with the consent of both companies.

1. Background of expiration of the Agreement

Nihon Kohden has worked on introduction, sales, and after-sales service of Abbott products in Japan for the past 38 years, including contracts with predecessor companies such as Daig Corporation and St. Jude Medical, Inc. The Company has also provided comprehensive solutions through the collaboration with AMJ based on the Agreement for their EP and CRM products signed in January 2022.

Under reviewing the Company’s business portfolio as part of its transformation into a global company creating high added value to realize its Long-term Vision toward 2030, Nihon Kohden has decided to terminate the Agreement on the expiration date of December 31, 2026, with the consent of both companies.

Nihon Kohden will discontinue providing all Abbott products on the same day.

We would like to express our heartfelt gratitude to all patients and medical institutions for their continued support over the years. Both companies are dedicated to ensuring a seamless transition of operations in collaboration with our distributors to minimize any inconvenience to patients and medical institutions during this process.

2. Expiration date of the Agreement

December 31, 2026

3. AMJ’s profile

(1) Name	Abbott Medical Japan LLC	
(2) Location	Shiodome City Center, Higashi Shimbashi 1-5-2, Minato-ku, Tokyo	
(3) Name and title of representative	Mayumi Chida, President and Representative Executive Officer	
(4) Business	Imports and sales of medical equipment	
(5) Date of establishment	March 8, 2011	
(6) Relationship between Nihon Kohden and AMJ	Capital	There is no significant relationship between Nihon Kohden and AMJ.
	Personnel	There is no significant relationship between Nihon Kohden and AMJ.
	Business	Nihon Kohden provides sales and after-sales service for Abbott products.
	Related parties	Not applicable.

4. Future outlook

(1) Future responses

From October 1, 2025 to December 31, 2026, Nihon Kohden will transfer its sales and after-sales service operations to AMJ in a phased manner.

(2) Financial results

The impact of this matter on the consolidated results for FY2025 ending March 31, 2026 is expected to be minor, while certain expenses for implementing the Career Change Support Program for employees engaged in the Company's Abbott business are expected to occur. For further details on the Career Change Support Program, please refer to the Notice of Implementation of Career Change Support Program and Next Career Support Program for Employees announced today. If an event which is required to be disclosed arises, the Company will immediately announce such event.

The impact on the consolidated results for FY2026 ending March 31, 2027 is currently under review and will be released at the time of the announcement of FY2025 results scheduled in May 2026. Through the reorganization of the Company's business portfolio, Nihon Kohden will further focus on providing its in-house products, consumables, and services, which account for 73.6% of consolidated sales in FY2024. The Company also aims to achieve medium- to long-term growth in domestic business by strengthening its sales capabilities in growth areas such as ventilators and digital health solutions (DHS).

* In FY2024, sales of Abbott products were ¥24.4 billion, a 10.8% of consolidated sales.

As the Company operates a single segment of medical electronic equipment-related business, operating income, number of employees, and assets are not divided into each product category.